Download PDF
Horm Metab Res 2011; 43(09): 625-630
DOI: 10.1055/s-0031-1283147
Original Basic
Georg Thieme Verlag KG Stuttgart · New York

Decrease of Blood Lipids Induced by Shan-Zha (Fruit of Crataegus pinnatifida) is Mainly Related to an Increase of PPARα in Liver of Mice Fed High-Fat Diet

C.- S. Niu   *
1   Department of Nursing, Tzu Chi College of Technology, Hualien City, Taiwan, Republic of China
,
C.- T. Chen   *
2   Department of Pediatrics and Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan, Republic of China
,
L.- J. Chen
3   Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City, Taiwan, Republic of China
,
K.- C. Cheng
4   Department of Psychosomatic Internal Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima City, Japan
,
C.- H. Yeh
5   Institute of Medical Sciences, Chang Jung Christian University, Quei-Jen, Tainan City, Taiwan, Republic of China
,
J.- T. Cheng
2   Department of Pediatrics and Medical Research, Chi-Mei Medical Center, Yong Kang, Tainan City, Taiwan, Republic of China
3   Institute of Basic Medical Sciences, College of Medicine, National Cheng Kung University, Tainan City, Taiwan, Republic of China
5   Institute of Medical Sciences, Chang Jung Christian University, Quei-Jen, Tainan City, Taiwan, Republic of China
› Author Affiliations
Further Information

Publication History

received 01 June 2011

accepted 21 June 2011

Publication Date:
05 August 2011 (online)

Also available at
    Permissions and Reprints

Abstract

Hyperlipidemia is an important risk factor for cardiovascular diseases. Agents for the treatment of hyperlipidemia are well-developed in the clinic while PPARα is a target for lipid-lowering agents. Shan-Zha (Crataegus pinnatifida) is a traditional Chinese medicine used to increase digestion. Also, Shan-Zha fruit extract showed merit to improve obesity and hyperlipidemia in hamsters; however, the mechanism remained obscure. In the present study, hypertriglycemia and hypercholesterolemia were induced by high fat diet in C57BL/6 J male mice. Then, they were orally administered with Shan-Zha fruit extract at an effective dose of 250 mg/kg for 7 days. The liver was removed to estimate the expressions of PPARα and β-oxidation-related enzyme. Oral intake of Shan-Zha extract significantly improved hyperlipidemia in high fat diet-fed mice with an increase of PPARα expression in liver. Also, expression of PPARα-regulated β-oxidation-related enzymes was raised in liver by Shan-Zha extract. However, adipose tissue and others were not modified by this treatment of Shan-Zha fruit extract. Thus, Shan-Zha can increase the expression of PPARα to facilitate β-oxidation-related enzymes in liver for lipid degradation and blood lipid decrement. Also, this is the first report showing Shan-Zha fruit extract can influence liver to lower hyperlipidemia prior to the action in adipose tissue.

Key words

Shan-Zha - hyperlipidemia - peroxisome proliferator-activated receptor α - lipid oxidation - liver - mice
*

* These authors contributed equally to this study.


 

  • References

  • 1 Ahmed SM, Clasen ME, Donnelly JE. Management of dyslipidemia in adults. Am Fam Physician 1998; 57: 2192-2204 2207–2198
    PubMedGoogle Scholar
  • 2 McBride P. Triglycerides and risk for coronary artery disease. Curr Atheroscler Rep 2008; 10: 386-390
    CrossrefPubMedGoogle Scholar
  • 3 Hamilton M. Strategies for the management of patients with obesity. Treat Endocrinol 2002; 1: 21-36
    CrossrefPubMedGoogle Scholar
  • 4 Yin J, Zhang H, Ye J. Traditional chinese medicine in treatment of metabolic syndrome. Endocr Metab Immune Disord Drug Targets 2008; 8: 99-111
    CrossrefPubMedGoogle Scholar
  • 5 Francis GA, Annicotte JS, Auwerx J. PPAR agonists in the treatment of atherosclerosis. Curr Opin Pharmacol 2003; 3: 186-191
    CrossrefPubMedGoogle Scholar
  • 6 Goldwasser J, Cohen PY, Yang E, Balaguer P, Yarmush ML, Nahmias Y. Transcriptional regulation of human and rat hepatic lipid metabolism by the grapefruit flavonoid naringenin: role of PPARalpha, PPARgamma and LXRalpha. PLoS One 2010; 5: e12399
    CrossrefPubMedGoogle Scholar
  • 7 Song S, Attia RR, Connaughton S, Niesen MI, Ness GC, Elam MB, Hori RT, Cook GA, Park EA. Peroxisome proliferator activated receptor alpha (PPARalpha) and PPAR gamma coactivator (PGC-1alpha) induce carnitine palmitoyltransferase IA (CPT-1A) via independent gene elements. Mol Cell Endocrinol 2010; 325: 54-63
    CrossrefPubMedGoogle Scholar
  • 8 Akbiyik F, Cinar K, Demirpence E, Ozsullu T, Tunca R, Haziroglu R, Yurdaydin C, Uzunalimoglu O, Bozkaya H. Ligand-induced expression of peroxisome proliferator-activated receptor alpha and activation of fatty acid oxidation enzymes in fatty liver. Eur J Clin Invest 2004; 34: 429-435
    CrossrefPubMedGoogle Scholar
  • 9 Luci S, Giemsa B, Kluge H, Eder K. Clofibrate causes an upregulation of PPAR-{alpha} target genes but does not alter expression of SREBP target genes in liver and adipose tissue of pigs. Am J Physiol Regul Integr Comp Physiol 2007; 293: R70-R77
    CrossrefPubMedGoogle Scholar
  • 10 Chu CY, Lee MJ, Liao CL, Lin WL, Yin YF, Tseng TH. Inhibitory effect of hot-water extract from dried fruit of Crataegus pinnatifida on low-density lipoprotein (LDL) oxidation in cell and cell-free systems. J Agric Food Chem 2003; 51: 7583-7588
    CrossrefPubMedGoogle Scholar
  • 11 Vibes J, Lasserre B, Gleye J, Declume C. Inhibition of thromboxane A2 biosynthesis in vitro by the main components of Crataegus oxyacantha (Hawthorn) flower heads. Prostaglandins Leukot Essent Fatty Acids 1994; 50: 173-175
    CrossrefPubMedGoogle Scholar
  • 12 Zhang Z, Chang Q, Zhu M, Huang Y, Ho WK, Chen Z. Characterization of antioxidants present in hawthorn fruits. J Nutr Biochem 2001; 12: 144-152
    CrossrefPubMedGoogle Scholar
  • 13 Al Makdessi S, Sweidan H, Mullner S, Jacob R. Myocardial protection by pretreatment with Crataegus oxyacantha: an assessment by means of the release of lactate dehydrogenase by the ischemic and reperfused Langendorff heart. Arzneimittelforschung 1996; 46: 25-27
    PubMedGoogle Scholar
  • 14 Popping S, Rose H, Ionescu I, Fischer Y, Kammermeier H. Effect of a hawthorn extract on contraction and energy turnover of isolated rat cardiomyocytes. Arzneimittelforschung 1995; 45: 1157-1161
    PubMedGoogle Scholar
  • 15 Weihmayr T, Ernst E. Therapeutic effectiveness of Crataegus. Fortschr Med 1996; 114: 27-29
    PubMedGoogle Scholar
  • 16 Ammon HP, Handel M. Crataegus, toxicology and pharmacology. Part III: Pharmacodynamics and pharmacokinetics. Planta Med 1981; 43: 313-322
    Article in Thieme ConnectPubMedGoogle Scholar
  • 17 Chen JD, Wu YZ, Tao ZL, Chen ZM, Liu XP. Hawthorn (shan zha) drink and its lowering effect on blood lipid levels in humans and rats. World Rev Nutr Diet 1995; 77: 147-154
    PubMedGoogle Scholar
  • 18 Kuo DH, Yeh CH, Shieh PC, Cheng KC, Chen FA, Cheng JT. Effect of shanzha, a Chinese herbal product, on obesity and dyslipidemia in hamsters receiving high-fat diet. Journal of Ethnopharmacology 2009; 124: 544-550
    CrossrefPubMedGoogle Scholar
  • 19 Wang SR, Pessah M, Infante J, Catala D, Salvat C, Infante R. Lipid and lipoprotein metabolism in Hep G2 cells. Biochim Biophys Acta 1988; 961: 351-363
    CrossrefPubMedGoogle Scholar
  • 20 Berger JP, Akiyama TE, Meinke PT. PPARs: therapeutic targets for metabolic disease. Trends Pharmacol Sci 2005; 26: 244-251
    CrossrefPubMedGoogle Scholar
  • 21 Kota BP, Huang TH, Roufogalis BD. An overview on biological mechanisms of PPARs. Pharmacol Res 2005; 51: 85-94
    CrossrefPubMedGoogle Scholar
  • 22 Yessoufou A, Wahli W. Multifaceted roles of peroxisome proliferator-activated receptors (PPARs) at the cellular and whole organism levels. Swiss Med Wkly 2010; 140: w13071
    PubMedGoogle Scholar
  • 23 Hashimoto T, Cook WS, Qi C, Yeldandi AV, Reddy JK, Rao MS. Defect in peroxisome proliferator-activated receptor alpha-inducible fatty acid oxidation determines the severity of hepatic steatosis in response to fasting. J Biol Chem 2000; 275: 28918-28928
    CrossrefPubMedGoogle Scholar
  • 24 Kersten S, Seydoux J, Peters JM, Gonzalez FJ, Desvergne B, Wahli W. Peroxisome proliferator-activated receptor alpha mediates the adaptive response to fasting. J Clin Invest 1999; 103: 1489-1498
    CrossrefPubMedGoogle Scholar
  • 25 Leone TC, Weinheimer CJ, Kelly DP. A critical role for the peroxisome proliferator-activated receptor alpha (PPARalpha) in the cellular fasting response: the PPARalpha-null mouse as a model of fatty acid oxidation disorders. Proc Natl Acad Sci USA 1999; 96: 7473-7478
    CrossrefPubMedGoogle Scholar
  • 26 Martin G, Schoonjans K, Lefebvre AM, Staels B, Auwerx J. Coordinate regulation of the expression of the fatty acid transport protein and acyl-CoA synthetase genes by PPARalpha and PPARgamma activators. J Biol Chem 1997; 272: 28210-28217
    CrossrefPubMedGoogle Scholar
  • 27 Sato O, Kuriki C, Fukui Y, Motojima K. Dual promoter structure of mouse and human fatty acid translocase/CD36 genes and unique transcriptional activation by peroxisome proliferator-activated receptor alpha and gamma ligands. J Biol Chem 2002; 277: 15703-15711
    CrossrefPubMedGoogle Scholar
  • 28 Oaxaca-Castillo D, Andreoletti P, Vluggens A, Yu S, van Veldhoven PP, Reddy JK, Cherkaoui-Malki M. Biochemical characterization of two functional human liver acyl-CoA oxidase isoforms 1a and 1b encoded by a single gene. Biochem Biophys Res Commun 2007; 360: 314-319
    CrossrefPubMedGoogle Scholar
  • 29 Wanders RJ. Peroxisomes, lipid metabolism, and peroxisomal disorders. Mol Genet Metab 2004; 83: 16-27
    CrossrefPubMedGoogle Scholar
  • 30 Fan CY, Pan J, Chu R, Lee D, Kluckman KD, Usuda N, Singh I, Yeldandi AV, Rao MS, Maeda N, Reddy JK. Hepatocellular and hepatic peroxisomal alterations in mice with a disrupted peroxisomal fatty acyl-coenzyme A oxidase gene. J Biol Chem 1996; 271: 24698-24710
    CrossrefPubMedGoogle Scholar
  • 31 Gao XF, Chen W, Kong XP, Xu AM, Wang ZG, Sweeney G, Wu D. Enhanced susceptibility of Cpt1c knockout mice to glucose intolerance induced by a high-fat diet involves elevated hepatic gluconeogenesis and decreased skeletal muscle glucose uptake. Diabetologia 2009; 52: 912-920
    CrossrefPubMedGoogle Scholar
  • 32 Sullivan MP, Cerda JJ, Robbins FL, Burgin CW, Beatty RJ. The gerbil, hamster, and guinea pig as rodent models for hyperlipidemia. Lab Animal Sci 1993; 43: 575-578
    PubMedGoogle Scholar
  • 33 Taghibiglou C, Rashid-Kolvear F, Van Iderstine SC, Le-Tien H, Fantus IG, Lewis GF, Adeli K. Hepatic very low density lipoprotein-ApoB overproduction is associated with attenuated hepatic insulin signaling and overexpression of protein-tyrosine phosphatase 1B in a fructose-fed hamster model of insulin resistance. The Journal of Biological Chemistry 2002; 277: 793-803
    PubMedGoogle Scholar
  • 34 Barbosa CR, Albuquerque EM, Faria EC, Oliveira HC, Castilho LN. Opposite lipemic response of Wistar rats and C57BL/6 mice to dietary glucose or fructose supplementation. Brazilian J Med Biol Res 2007; 40: 323-331
    CrossrefPubMedGoogle Scholar
  • 35 Paquette A, Chapados NA, Bergeron R, Lavoie JM. Fatty acid oxidation is decreased in liver of ovariectomized rats. Hormone and Metabolic Research 2009; 41: 511-515
    Article in Thieme ConnectPubMedGoogle Scholar